|本期目录/Table of Contents|

[1]王娟,夏超.响应面法优化制备蓝萼甲磺丁醚-β-环糊精包合物及体外活性研究[J].医学研究与战创伤救治(原医学研究生学报),2021,23(6):627-632.[doi:10.3969/j.issn.1672-271X.2021.06.015]
　WANG Juan,XIA Chao.Optimization of preparation and in vitro bioactivity study of blue calyx mesylate-β-cyclodextrin inclusion complex by response surface methodology[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(6):627-632.[doi:10.3969/j.issn.1672-271X.2021.06.015]
点击复制

响应面法优化制备蓝萼甲磺丁醚-β-环糊精包合物及体外活性研究()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年6期
页码:
627-632
栏目:
药学研究
出版日期:
2021-12-15

文章信息/Info

Title:
Optimization of preparation and in vitro bioactivity study of blue calyx mesylate-β-cyclodextrin inclusion complex by response surface methodology
作者:
王娟; 夏超
作者单位：210009南京，江苏省人民医院麻醉与围术期医学科（王娟 ）；210002南京，江苏省药物研究所有限公司（夏超）
Author(s):
WANG Juan;  XIA Chao
（1. Department of Anesthesia and Perioperative Medicine，Jiangsu Provincial People’s Hospital, Nanjing 210009，Jiangsu, China；2. Preparation Room of Pharmacy Department, Jiangsu Provincial Institue of Meteria Medica, Nanjing 210002, Jiangsu, China）
关键词:
蓝萼甲素A; 磺丁基醚β-环糊精; 包合物; 溶解度; 抑制癌细胞
Keywords:
glaucocalysin A;  sulfobutyl ether β-cyclodextrin;  inclusion complex;  solubility;  inhibition of cancer cells
分类号:
R944.9
DOI:
10.3969/j.issn.1672-271X.2021.06.015
文献标志码:
A
摘要:
目的采用包合物的制剂手段，改善蓝萼甲素A (GLA)水溶性，同时提高GLA抑制癌细胞增值的效果。方法采用 超声波法将GLA包封在磺丁基醚β-环糊精（SBE-β-CD）中形成包合物（GLA-SBE-β-CD），采用Box-Behnken设计优 化GLA-SBE-β-CD包合物的制备工艺，并且通过差示扫描量热法（DSC）、X射线衍射（XRD）和扫描电子显微镜（SEM ）对制备的包合物进行表征。最后，使用MTT法检测GLA和GLA-SBE-β-CD包合物对人宫颈癌细胞Hela、人肺癌细胞 A549、人肝癌细胞HepG2和人宫颈鳞癌细胞SiHA的抑制作用。结果一系列物理表征结果证实了GLA-SBE-β-CD包合物 被成功制备，在Box-Behnken优化的基础上获得87.28%的包合率；确定了SBE-β-CD浓度为18.5%，包合温度为35 ℃ ，包合时间为42 min。在最佳工艺条件下进行制备，平均产率为87.28%，相对标准偏差(RSD)为1.02%；同时人源癌 细胞抑制实验中GLA-SBE-β-CD对Hela、A549、HepG2和SiHA这4种肿瘤细胞的抑制率比纯GLA更高。结论通过超声波 法可成功制备GLA-SBE-β-CD包合物，该包合物在抑制肿瘤细胞生长方面明显高于原料药GLA，说明通过制剂手段能 够很好地提高原料药的药效作用，为能早日帮助患者摆脱病痛带来有价值的参考和制剂依据。
Abstract:
ObjectiveTo improve the poor water solubility of glaucocalysin A (GLA) and enhance the inhibitory effect of GLA on the proliferation of cancer cells by means of inclusion compound.MethodsGLA was encapsulated in sulfobutyl ether by ultrasonic method. β-Cyclodextrin (sulfobutyl ether) β-Cyclodextrin, SBE-β-Forming inclusion complex (GLA-SBE) in CD-β-GLA-SBE was optimized by Box-Behnken design. The inclusion complex was characterized by differential scanning calorimetry (DSC), X-ray diffraction (XRD) and scanning electron microscopy (SEM). Finally, GLA and GLA-SBE-β-CD were detected by MTT method. The inhibitory effect of CD inclusion complex on HeLa, A549, HepG2 and SiHa human cancer cells was studied.ResultsA series of physical characterization results confirmed GLA-SBE-β-CD on the basis of Box-Behnken optimization. The inclusion rate was 87.28%. The concentration of GLA-SBE-β-CD was 18.5%. The inclusion temperature was 35℃, and the inclusion time was 42 min. The aver- age yield was 87.28%, and the relative standard deviation (RSD) was 1.02%. At the same time, GLA-SBE- β-CD was detected in the inhibition test of human cancer cells. The inhibition rate of GLA-SBE-β-CD on these four kinds of tumor cells was higher than that of pure GLA.ConclusionGLA-SBE-β-CD is successfully prepared by ultrasonic method. The inclusion complex of GLA-SBE-β-CD can significantly inhibit the growth of cancer cells, which is higher than that of GLA, which does not form the inclusion complex. It shows that the drug efficacy of the drug can be improved by means of preparation, which can provide valuable reference and preparation basis for helping patients get rid of pain as soon as possible.

参考文献/References:

[1]李昌辉, 孟玲, 桂霞,等. 一种提取与分离冬凌草甲素的方法[J]. 化工学报, 2018, 69(S2):250-255.
[2]纠敏, 闫鹏, 李晶晶,等. 冬凌草甲素对金黄色葡萄球菌生物膜的抑制机制[J]. 微生物学通报, 2020, 47 (5):250-256.
[3]代丽萍, 赵猛, 时博,等. 一种从毛叶香茶菜中制备冬凌草甲素的方法[P]. 中国专利：CN105732653B，2017-12 -15.
[4]姚士, 褚纯隽, 韩海燕,等. 蓝萼甲素抗血栓作用研究[J]. 辽宁中医药大学学报, 2012, 14(11):61-65..
[5]Yang F,Cao Y,Zhang J,et al. Glaucocalyxin A improves survival in bleomycin-induced pulmonary fibrosis in mice[J]. Biochem Biophy Res Comm, 2017,482(1):147-153..
[6]朱庆, 曹燕丽, 徐云燕,等. 酸变性法构建转铁蛋白-姜黄素纳米粒子及其肿瘤靶向性[J]. 东南国防医药, 2019 ，21(3)：262-266.
[7]李云森, 陈子珺, 邓世平,等. 蓝萼甲素衍生物及其药学上可接受的盐的剂型[P]. 中国，CN104887652A，2015- 09-09.
[8]郄淑燕, 郝莹, 刘宗建,等. 环糊精聚合物及其生物医学应用的研究进展[J]. 化学学报, 2020, 78(3):48-60.
[9]Amin OM, Ammar A, Eladawy SA. Febuxostat loaded β-cyclodextrin based nanosponge tablet: an in vitro and in vivo evaluation [J]. J Pharm Investig, 2020, 50(4):399-411.
[10]郝彬彬, 王芹, 任勇,等. 羟丙基-β-环糊精包合物中尼非韦罗含量测定和稳定性考察[J]. 医学研究生学报, 2011，24(6):565-568.
[11]徐康, 林正. 自由基对转录因子NF-κB活性的调节[J]. 医学研究生学报, 2004, 17(7):654-656.
[12]Zhou X, Kong L, Jing Z，et al. Facile synthesis of superparamagnetic β-CD-MnFe2O4 as a peroxymonosulfate activator for efficient removal of 2,4- dichlorophenol: Structure, performance, and mechanism[J]. J Hazard Mater, 2020,394:122528. doi: 10.1016/j.jhazmat.2020.122528.
[13]王学文. 抗肿瘤治疗新药蛋白酶体抑制剂Bortezomib的临床应用[J]. 东南国防医药, 2016, 8(6):473-478.
[14]Pan H, Wang HB, Yu YB, et al. Original research paper. A superior preparation method for daidzein-hydroxypropyl-β-cyclodextrin complexes with improved solubility and dissolution: Supercritical fluid process[J]. Acta Pharm, 2017, 67(1): 85-96.
[15]Zarandona I, Barba C, Guerrero P, et al. Development of chitosan films containing β-cyclodextrin inclusion complex for controlled release of bioactives[J]. Food Hydr, 2020, 104(12):105720-105733.
[16]Esmaeilpour D, Shityakov S, Tamaddon AM, et al. Comparative chemical examination of inclusion complexes formed with β-cyclodextrin derivatives and basis amino acids[J]. Carbohydr Polym，2021, 262:117868.doi: 10.1016/j.carbpol.2021.117868.

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-12-15